AzTrials
AzTrials

Arthritis, RheumatoidPhase 2NCT00634933

Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid Arthritis

A Phase 2 study testing TRU-015, Methylprednisolone and Prednisone in people with Arthritis, Rheumatoid, run by Pfizer at 65 sites in 10 countries.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

This study will evaluate the efficacy and safety of two dosing regimens of a compound known as TRU-015 in combination with methotrexate (MTX) in patients with active rheumatoid arthritis. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Arthritis, Rheumatoid
What is being tested?
TRU-015, Methylprednisolone and Prednisone
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
222 participants
Where
65 sitesin 10 countries
Study dates
Mar 2008to Oct 2012
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Clinical diagnosis of active seropositive rheumatoid arthritis on a stable dose of methotrexate (7.5-25 mg weekly) for at least 12 weeks with or without a history of anti-TNF use.

Who cannot join

  • Any prior use of rituximab or other B cell depleting agents.
  • Any significant health problem other than rheumatoid arthritis
  • Clinically significant laboratory abnormalities

Trial locations and contacts

65 sites in 10 countries.

65 sites in 10 countries

United States29 sites
  • Pfizer Investigational Site

    Birmingham, Alabama, 35294-7201

  • Pfizer Investigational Site

    Charlotte, North Carolina, 28210

  • Pfizer Investigational Site

    Chicago, Illinois, 60612

  • Pfizer Investigational Site

    Cincinnati, Ohio, 45245

  • Pfizer Investigational Site

    Clarksburg, West Virginia, 26301

  • Pfizer Investigational Site

    Dallas, Texas, 75231

  • Pfizer Investigational Site

    Danville, Pennsylvania, 17822

  • Pfizer Investigational Site

    Daytona Beach, Florida, 32117

  • Pfizer Investigational Site

    Flowood, Mississippi, 39232

  • Pfizer Investigational Site

    Grande Rapids, Michigan, 49546

  • Pfizer Investigational Site

    Los Angeles, California, 90048

  • Pfizer Investigational Site

    Los Angeles, California, 90095

  • Pfizer Investigational Site

    Mayfield Village, Ohio, 44143

  • Pfizer Investigational Site

    Minot, North Dakota, 58701

  • Pfizer Investigational Site

    Ocala, Florida, 34474

  • Pfizer Investigational Site

    Oklahoma City, Oklahoma, 73112

  • Pfizer Investigational Site

    Palm Harbor, Florida, 34684

  • Pfizer Investigational Site

    Paradise Valley, Arizona, 85253

  • Pfizer Investigational Site

    San Antonio, Texas, 78232

  • Pfizer Investigational Site

    Santa Maria, California, 93454-6945

  • Pfizer Investigational Site

    Santa Monica, California, 90404

  • Pfizer Investigational Site

    Springfield, Illinois, 62704

  • Pfizer Investigational Site

    St Louis, Missouri, 63110

  • Pfizer Investigational Site

    State College, Pennsylvania, 16801

  • Pfizer Investigational Site

    Syracuse, New York, 13210

  • Pfizer Investigational Site

    Wexford, Pennsylvania, 15090

  • Pfizer Investigational Site

    Wilkes-Barre, Pennsylvania, 18711-3762

  • Pfizer Investigational Site

    Worcester, Massachusetts, 01605

  • Pfizer Investigational Site

    Worcester, Massachusetts, 01608

Other trials in United States

Mexico8 sites
  • Pfizer Investigational Site

    Culiacán, Sinaloa/Mexico, 80020

  • Pfizer Investigational Site

    Guadalajara, Jalisco, 44100

  • Pfizer Investigational Site

    Guadalajara, Jalisco, 44158

  • Pfizer Investigational Site

    Guadalajara, Jalisco, 44650

  • Pfizer Investigational Site

    Guadalajara, Jalisco, 44690

  • Pfizer Investigational Site

    Mexicali, Baja California/Mexico, 21100

  • Pfizer Investigational Site

    Mexico City, 06700

  • Pfizer Investigational Site

    Morelia, Michoacán, 58070

Other trials in Mexico

Canada7 sites
  • Pfizer Investigational Site

    Kelowna, British Columbia, V1W 4V5

  • Pfizer Investigational Site

    Kelowna, British Columbia, V1Y 3G8

  • Pfizer Investigational Site

    Kitchener, Ontario, N2M 5N6

  • Pfizer Investigational Site

    Saskatoon, Saskatchewan, S7N 0W8

  • Pfizer Investigational Site

    Sydney, Nova Scotia, B1S 3N1

  • Pfizer Investigational Site

    Trois-Rivières, Quebec, G8Z 1Y2

  • Pfizer Investigational Site

    Winnipeg, Manitoba, R3A 1M3

Other trials in Canada

Germany5 sites
  • Pfizer Investigational Site

    Cologne, 50924

  • Pfizer Investigational Site

    Essen, 45239

  • Pfizer Investigational Site

    Vogelsang, Gommern, 39245

  • Pfizer Investigational Site

    Würzburg, 97070

  • Pfizer Investigational Site

    Würzburg, 97080

Other trials in Germany

Romania5 sites
  • Pfizer Investigational Site

    Bucharest, Romania, 020983

  • Pfizer Investigational Site

    Bucharest, 011172

  • Pfizer Investigational Site

    Bucharest, 020983

  • Pfizer Investigational Site

    Cluj-Napoca, Romania, 400006

  • Pfizer Investigational Site

    Iași, Iaşi, 700081

Other trials in Romania

France3 sites
  • Pfizer Investigational Site

    Montpellier, France, 34059

  • Pfizer Investigational Site

    Paris, 75674

  • Pfizer Investigational Site

    Toulouse, 31059

Other trials in France

Hungary3 sites
  • Pfizer Investigational Site

    Budapest, 1023

  • Pfizer Investigational Site

    Debrecen, 4043

  • Pfizer Investigational Site

    Nyíregyháza, 4400

Other trials in Hungary

Belgium2 sites
  • Pfizer Investigational Site

    Brussels, 1200

  • Pfizer Investigational Site

    Liège, 4000

Other trials in Belgium

Serbia2 sites
  • Pfizer Investigational Site

    Belgrade, 11000

  • Pfizer Investigational Site

    Niška Banja, 18250

Other trials in Serbia

Netherlands1 site
  • Pfizer Investigational Site

    Leiden, 2333 ZA

Other trials in Netherlands

About this study

Official title: A Randomized, Parallel, Double-Blind, Placebo-Controlled Dose Regimen Finding Study To Evaluate The Safety And Efficacy Of TRU-015 In Subjects With Active Seropositive Rheumatoid Arthritis On A Stable Background Of Methotrexate

This study will evaluate the efficacy and safety of two dosing regimens of a compound known as TRU-015 in combination with methotrexate (MTX) in patients with active rheumatoid arthritis.

Being tested
TRU-015, Methylprednisolone, Prednisone
Keywords
active, rheumatoid, arthritis, anti CD20
Medical subject headings
Arthritis, Rheumatoid, Motor Activity, Arthritis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • TRU-015Drug

    IV 800 mg TRU-015 at Baseline (both arms) and Week 24 (both arms); corresponding IV Placebo at Week 12 and Week 36 (both arms).

  • MethylprednisoloneDrug

    IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (arm 1a) and Week 24 (both arms); corresponding IV Placebo at Week 12 (Arm 1b) and Week 36 (both arms).

  • PrednisoneDrug

    Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 1a), and Week 24 (both arms); corresponding Oral Placebo at Week 12 (Arm 1b) and Week 36 (both arms)

  • TRU-015Drug

    IV 800 mg TRU-015 at Baseline (both arms), Week 12 (both arms), and Week 36 (both arms); corresponding IV Placebo at Week 24 (both arms).

  • MethylprednisoloneDrug

    IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (both arms), and Week 36 (both arms); corresponding IV Placebo at Week 36 (both arms).

  • PrednisoneDrug

    Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 2a) and Week 36 (both arms); corresponding Oral Placebo at Week 12 (Arm 2b) and Week 24 (both arms).

  • TRU-015Drug

    IV 800 mg TRU-015 at Week 24 (both arms) and Week 36 (arm 3a); corresponding IV Placebo at Baseline (both arms), Week 12 (both arms) and Week 36 (arm 3b).

  • MethylprednisoloneDrug

    IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (arm 3a), Week 24 (both arms), and Week 36 (arm 3a); corresponding IV Placebo at Week 12 (arm 3b) and Week 36 (arm 3b).

  • PrednisoneDrug

    Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 3a), Week 24 (both arms) and Week 36 (arm 3a); corresponding Oral Placebo at Week 12 (Arm 3b) and Week 36 (arm 3b).

Study groups in NCT00634933
Study groupRoleWhat they receive
Arm 1ExperimentalConsists of Arms 1a and 1b
Receives: Drug: TRU-015; Drug: Methylprednisolone; Drug: Prednisone
Arm 2ExperimentalConsists of Arms 2a and 2b
Receives: Drug: TRU-015; Drug: Methylprednisolone; Drug: Prednisone
Arm 3Placebo comparatorConsists of Arms 3a and 3b.
Receives: Drug: TRU-015; Drug: Methylprednisolone; Drug: Prednisone

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants With an American College of Rheumatology 50% (ACR 50) Response at Week 24

    ACR50 response: greater than or equal to (>=) 50 percent (%) improvement in tender joint count; >=50% improvement in swollen joint count; and >=50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ-DI]); and C-Reactive Protein (CRP).

    Measured: Week 24

Secondary outcomes (18)
  1. Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response

    ACR20 response: >= 20% improvement in tender joint count; >= 20% improvement in swollen joint count; and >= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (HAQ-DI); and CRP.

    Measured: Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52

  2. Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response

    ACR50 response: >=50% improvement in tender joint count; >=50% improvement in swollen joint count; and >=50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (HAQ-DI); and CRP.

    Measured: Week 2, 4, 8, 12, 16, 20, 28, 32, 36, 40, 44, 48, 52

  3. Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response

    ACR70 response: >=70% improvement in tender joint count; >=70% improvement in swollen joint count; and >=70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (HAQ-DI); and CRP.

    Measured: Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52

  4. Number of Tender Joints

    The number of tender joints was determined by examining 28 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1.

    Measured: Baseline, Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52

  5. Number of Swollen Joints

    The number of swollen joints was determined by examination of 28 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1.

    Measured: Baseline. Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52

  6. Duration of Morning Stiffness

    Duration of morning stiffness is defined as the time elapsed when participant woke up in the morning and was able to resume normal activities without stiffness in minutes (if none was present = 0; if morning stiffness was continuing, average of duration of stiffness over the past 3 days was reported; if stiffness persisted the entire day, 1440 minutes [24 hours*60 minutes] was recorded).

    Measured: Baseline, Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52

  7. Visual Analogue Scale for Pain (VAS-pain)

    100 millimeter (mm) line (Visual Analog Scale) marked by participant. Intensity of pain range (over past week): 0 = no pain to 100 = worst possible pain.

    Measured: Baseline, Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52

  8. Physician Global Assessment (PGA) of Disease Activity

    Physician Global Assessment of Disease Activity was measured on a 0 to 10 point scale, where 0 = no disease activity and 10 = extreme disease activity.

    Measured: Baseline, Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52

  9. Patient Global Assessment (PtGA) of Disease Activity

    Measured using a 0-10 point scale, where 0 = no disease activity and 10 = extreme disease activity.

    Measured: Baseline, Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52

  10. General Health Visual Analog Scale (VAS)

    100 mm line (VAS) marked by participant. Participants were asked, "How do you feel concerning your arthritis?" Total possible score range, 0 mm = very well to 100 mm = extremely bad.

    Measured: Baseline, Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52

  11. Health Assessment Questionnaire Disability Index (HAQ-DI)

    HAQ-DI: participant-reported assessment of ability to perform tasks: 1) dress/groom; 2) arise; 3) eat; 4) walk; 5) reach; 6) grip; 7) hygiene; and 8) common activities over past week. Each item scored on 4-point Likert scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. The overall disability index computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.

    Measured: Baseline, Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52

  12. Disease Activity Score Based on 28-joints Count (DAS28)

    DAS28 calculated from the number of swollen joints (SJC) and painful joints (PJC) using the 28 joints count, the erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hour]) and participant's general health visual analog scale (scores ranging 0 [very well] to 100 mm [extremely bad]). DAS28 less than or equal to (=<) 3.2 = low disease activity, DAS28 greater than (>) 3.2 to 5.1 = moderate to high disease activity.

    Measured: Baseline, Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52

  13. 36-Item Short-Form Health Survey (SF-36)

    SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).

    Measured: Baseline, Week 12, 24, 36, 52

  14. Euro Quality of Life (EQ-5D)- Health State Profile Utility Score

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (eg, "confined to bed"). Scoring formula developed by EuroQol Group assigns utility value for each domain in the profile. Score is transformed and results in total score range -0.594 to 1.000; higher score indicates a better health state.

    Measured: Baseline, Week 12, 24, 36, 52

  15. Euro Quality of Life (EQ-5D)- Visual Analog Scale (VAS)

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.

    Measured: Baseline, Week 12, 24, 36, 52

  16. Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score

    FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (not at all) to 4 (very much). Larger the participant's response to the questions (with the exception of 2 negatively stated), greater was the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score).

    Measured: Baseline, Week 12, 24, 36, 52

  17. Work Productivity and Activity Impairment Questionnaire: Rheumatoid Arthritis (WPAI-RA) Score

    WPAI-RA consisted of 6 items, a binary question on current employment, 3 questions on hours of work and work-loss, and 2 questions based on 0-10 point scale to judge how RA affects productivity at work and outside of work (0 = no effect on work and 10 = completely prevented from working). Four scores are derived: percent work time missed due to health, percent impairment while working due to health, percent overall work impairment due to health and percent activity impairment due to health. Total possible score range: 0 to 100, where 0 = no impairment and 100 = completely impaired.

    Measured: Baseline, Week 12, 24, 36, 52

  18. Percentage of Participants With European League Against Rheumatism (EULAR) Response Based on DAS28

    The DAS28-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline >1.2 with DAS28 =< 3.2; moderate responders: change from baseline >1.2 with DAS28 >3.2 to =<5.1 or change from baseline >0.6 to =<1.2 with DAS28 =<5.1; non-responders: change from baseline =< 0.6 or change from baseline >0.6 and =<1.2 with DAS28 >5.1.

    Measured: Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Mar 2008 (estimated)
  2. Study startMar 2008
  3. Primary completionFeb 2010
  4. Study completionOct 2012

Why it stopped: The study was terminated on 21 June 2010 due to results not meeting the primary endpoint. No safety reasons contributed to the termination of the study.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
222 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00634933
Sponsor's protocol ID
3206K1-2203
Other IDs
B2051001
Status last verified
Feb 2013
First submitted
5 Mar 2008
Last updated
11 Mar 2013
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing TRU-015, Methylprednisolone and Prednisone in people with Arthritis, Rheumatoid, run by Pfizer at 65 sites in 10 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 11 Mar 2013. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 65 sites in United States, Mexico, Canada, Germany, Romania and 5 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 11 Mar 2013). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Participants With an American College of Rheumatology 50% (ACR 50) Response at Week 24 (time frame: Week 24). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Mar 2013.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in